Ads
related to: car t multiple myeloma 2025- Primary and Subgroup Data
Primary- and Subgroup-
Specific Data
- Phase 3 Trial
Explore the Phase 3 Trial Design,
Results, and Patient Population
- Contact a Representative
For Questions and Information
About This Treatment
- Patient Profile
Potential Treatment Candidates
HCPs, See Who May Be Appropriate
- Primary and Subgroup Data
Search results
Results from the WOW.Com Content Network
CAR T Cell Therapies with Regulatory Approval; ... (CAR) T-cell treatment for multiple myeloma. ... This page was last edited on 10 February 2025, ...
The major application of CAR-T immunotherapy is to treat hematological malignancies, such as multiple myeloma, chronic lymphocytic leukemia, acute lymphoblastic leukemia and lymphoma. [8] Also, CAR-T-related solid tumor treatments have become increasingly promising due to protein and cell engineering improvements. [9]
Multiple myeloma (MM), also known as plasma cell myeloma and simply myeloma, is a cancer of plasma cells, a type of white blood cell that normally produces antibodies. [6] Often, no symptoms are noticed initially. [10] As it progresses, bone pain, anemia, renal insufficiency, and infections may occur. [10]
Talquetamab, sold under the brand name Talvey, is a humanized monoclonal antibody used for the treatment of multiple myeloma. [ 1 ] [ 9 ] It is a bispecific GPRC5D-directed CD3 T-cell engager. [ 1 ]
Towana Looney of Alabama is 'going strong and feeling great' after a pig kidney transplant. No one has lived longer with an animal organ.
Doechii Denies Lip-Synching at 2025 Grammys, Says She Had Bronchitis and the Flu During Complex Performance The "NISSAN ULTIMA" singer won the Grammy for best rap album on Feb. 2 Parade 11 days ago
Ads
related to: car t multiple myeloma 2025